This study evaluates the safety, tolerability and preliminary antitumor activity of WX390, a PI3K-mTOR dual inhibitor, in combination with toripalimab, a PD-1 monoclonal antibody in advanced gastric-type endocervical adenocarcinoma with LKB1 mutations. Here, STK11 is linked to endocervical adenocarcinoma.